Nanobiotix Amends Licensing Deal With Johnson & Johnson

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Nanobiotix Amends Licensing Deal With Johnson & Johnson

, MT Newswires - 5:32 PM ET 3/17/2025 Company News

05:32 PM EDT, 03/17/2025 (MT Newswires) -- Nanobiotix ( NBTX ) said late Monday it has amended a global licensing deal for JNJ-1900 with Johnson & Johnson's ( JNJ ) Janssen Pharmaceutica, extending its cash visibility.

The amendment removed Nanobiotix's ( NBTX ) funding obligation for the NANORAY-312 trial, while releasing Johnson & Johnson ( JNJ ) from some potential milestone payments, Nanobiotix ( NBTX ) said.

"We are pleased by what we view as a favorable cost of capital resulting from this amendment," said Chief Financial and Business Officer Bart Van Rhijn.

Under the amended deal, Johnson & Johnson ( JNJ ) will cover NANORAY-312 costs through completion, Nanobiotix ( NBTX ) said, adding the value of the licensing deal has decreased to about $2.6 billion from about $2.7 billion.

The amended deal would extend its cash visibility to mid-2026, the firm said. It is also exploring financing options, preferably non-dilutive, to further extend its runway into 2027.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.